Journal ArticleDOI
Mitochondrial complex I deficiency in Parkinson's disease.
Reads0
Chats0
About:
This article is published in The Lancet.The article was published on 1989-06-03. It has received 1548 citations till now. The article focuses on the topics: NAD(P)H Dehydrogenase (Quinone) & Substantia nigra.read more
Citations
More filters
Journal ArticleDOI
The mitochondrial transcription factor TFAM in neurodegeneration: emerging evidence and mechanisms.
TL;DR: Evaluated potential associations of altered TFAM levels or mtDNA copy number with neurodegeneration, and potential mechanisms by which mtDNA replication, transcription initiation, and TFAM‐mediated endogenous danger signals may impact mitochondrial homeostasis in Alzheimer, Huntington, Parkinson, and other Neurodegenerative diseases are described.
Journal ArticleDOI
The MPTP model: versatile contributions to the treatment of idiopathic Parkinson's disease.
TL;DR: In human and subhuman primates, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine produces irreversible clinical, biochemical and neuropathological alterations highly reminiscent of those observed in Parkinson's disease.
Journal ArticleDOI
Mitochondrial dynamics in Parkinson's disease.
TL;DR: The current data suggests that mitochondrial dynamics may play a role in PD pathogenesis, and a better understanding of mitochondrial dynamics within the neuron may lead to future therapeutic treatments for PD, potentially aimed at some of the earliest pathogenic events.
Journal ArticleDOI
Selective binding of nuclear alpha-synuclein to the PGC1alpha promoter under conditions of oxidative stress may contribute to losses in mitochondrial function: Implications for Parkinson’s disease
Almas Siddiqui,Shankar J. Chinta,Jyothi K. Mallajosyula,Subramanian Rajagopolan,Ingrid M. Hanson,Anand Rane,Simon Melov,Julie K. Andersen +7 more
TL;DR: The data suggest that nuclear alpha-synuclein localization under conditions of oxidative stress may impact on mitochondrial function in part via the protein's capacity to act as a transcriptional modulator of PGC1alpha.
Journal ArticleDOI
Calcium and Parkinson's disease.
TL;DR: An ongoing, NIH sponsored, Phase 3 clinical trial in North America is testing the ability of one member of the dihydropyridine class (isradipine) to slow PD progression in early stage patients, and the review summarizes the rationale for the trial and outlines some unanswered questions.
Related Papers (5)
Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis
Mutation in the α-synuclein gene identified in families with Parkinson's disease
Mihael H. Polymeropoulos,Christian Lavedan,Elisabeth Leroy,Susan E. Ide,Anindya Dehejia,Amalia Dutra,Brian L. Pike,Holly Root,Jeffrey Rubenstein,Rebecca Boyer,Edward S. Stenroos,Settara C. Chandrasekharappa,Aglaia Athanassiadou,Theodore Papapetropoulos,William G. Johnson,Alice Lazzarini,Roger C. Duvoisin,Giuseppe Di Iorio,Lawrence I. Golbe,Robert L. Nussbaum +19 more
Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1
Eriza Maria Valente,Patrick M. Abou-Sleiman,Viviana Caputo,Miratul M. K. Muqit,Kirsten Harvey,Suzana Gispert,Zeeshan Ali,Domenico Del Turco,Anna Rita Bentivoglio,Daniel G. Healy,Alberto Albanese,Robert L. Nussbaum,Rafael González-Maldonado,Thomas Deller,S Salvi,Pietro Cortelli,William P. Gilks,David S. Latchman,Roberk J. Harvey,Bruno Dallapiccola,Georg Auburger,Nicholas W. Wood +21 more